# Novo Nordisk A/S: Phase 4 study in Cardiovascular Risk, Chronic Kidney Disease (300 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China |
| NCT ID | NCT07900438 |
| Phase | Phase 4 |
| Status | recruiting |
| Conditions | Cardiovascular Risk; Chronic Kidney Disease |
| Intervention types | drug |
| Target enrollment | 300 |
| Site countries | China |
| Posted | 2026-10-28 |
| Planned start | 2026-10-12 |
| Event | Newly registered study |
| Event date | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- 300 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07900438). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.